CA2932015A1 - Intracameral implant for treatment of an ocular condition - Google Patents

Intracameral implant for treatment of an ocular condition Download PDF

Info

Publication number
CA2932015A1
CA2932015A1 CA2932015A CA2932015A CA2932015A1 CA 2932015 A1 CA2932015 A1 CA 2932015A1 CA 2932015 A CA2932015 A CA 2932015A CA 2932015 A CA2932015 A CA 2932015A CA 2932015 A1 CA2932015 A1 CA 2932015A1
Authority
CA
Canada
Prior art keywords
implant
pharmaceutical composition
therapeutic agent
polymer matrix
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2932015A
Other languages
English (en)
French (fr)
Inventor
Benjamin Maynor
Andres Garcia
Sanjib Kumar Das
Tomas Navratil
Benjamin Robinson Yerxa
Janet Tully
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
ENVISIA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENVISIA THERAPEUTICS Inc filed Critical ENVISIA THERAPEUTICS Inc
Publication of CA2932015A1 publication Critical patent/CA2932015A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2932015A 2013-12-06 2014-12-05 Intracameral implant for treatment of an ocular condition Abandoned CA2932015A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361912867P 2013-12-06 2013-12-06
US61/912,867 2013-12-06
US201461926112P 2014-01-10 2014-01-10
US61/926,112 2014-01-10
US201461987902P 2014-05-02 2014-05-02
US61/987,902 2014-05-02
PCT/US2014/068925 WO2015085251A1 (en) 2013-12-06 2014-12-05 Intracameral implant for treatment of an ocular condition

Publications (1)

Publication Number Publication Date
CA2932015A1 true CA2932015A1 (en) 2015-06-11

Family

ID=53274192

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932015A Abandoned CA2932015A1 (en) 2013-12-06 2014-12-05 Intracameral implant for treatment of an ocular condition

Country Status (9)

Country Link
US (2) US20160296627A1 (ko)
EP (2) EP3861982A3 (ko)
JP (1) JP6546194B2 (ko)
KR (1) KR20160100992A (ko)
CN (1) CN106132397A (ko)
AU (1) AU2014360184B2 (ko)
CA (1) CA2932015A1 (ko)
MX (1) MX2016007345A (ko)
WO (1) WO2015085251A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
WO2017015675A1 (en) 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants
AU2016297187A1 (en) * 2015-07-23 2018-02-15 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
CA2995240A1 (en) 2015-08-14 2017-02-23 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
SG11201901588TA (en) * 2016-09-02 2019-03-28 Envisia Therapeutics Inc Implant applicators
CA3063847A1 (en) 2017-05-16 2018-11-22 Embody Inc. Biopolymer compositions, scaffolds and devices
EP3700462A4 (en) * 2017-10-24 2021-11-17 Embody Inc. BIOPOLYMER SCAFFOLDING IMPLANTS AND THEIR PRODUCTION METHODS
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
JP6990321B2 (ja) * 2018-02-22 2022-01-12 イバンティス インコーポレイテッド 眼用インプラントおよび送達システム
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
SG11202009246UA (en) * 2018-03-30 2020-10-29 Aerie Pharmaceuticals Inc Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
CN108815169A (zh) * 2018-05-23 2018-11-16 中南大学湘雅医院 一种前列腺素类物质组合得到有效的青光眼治疗剂
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
CN113874192B (zh) 2019-02-01 2024-01-02 恩博迪股份有限公司 微流体挤出
US20200306182A1 (en) * 2019-03-05 2020-10-01 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
SE543273C2 (en) 2019-03-29 2020-11-10 Tobii Ab Training an eye tracking model
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
JP7451732B2 (ja) 2020-02-06 2024-03-18 オキュラ セラピューティクス，インコーポレイテッド 眼疾患を治療するための組成物及び方法
BR112022018815A2 (pt) 2020-03-25 2022-11-29 Ocular Therapeutix Inc Implante ocular contendo um inibidor de tirosina cinase
WO2022150684A1 (en) 2021-01-11 2022-07-14 Ivantis, Inc. Systems and methods for viscoelastic delivery
CN114948851B (zh) * 2022-05-25 2024-03-08 北京航空航天大学 微创植入漂浮式可降解药物缓释植入物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997691B (zh) 2003-09-23 2011-07-20 北卡罗来纳大学查珀尔希尔分校 光固化的全氟聚醚用作微流体器件中的新材料
ES2625345T3 (es) 2003-12-19 2017-07-19 The University Of North Carolina At Chapel Hill Métodos para fabricar micro- y nanoestructuras usando litografía blanda o de impresión
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
EP2537657A3 (en) 2005-08-09 2016-05-04 The University of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
AU2007339929A1 (en) * 2006-12-26 2008-07-10 Qlt Inc. Drug delivery implants for inhibition of optical defects
PT3202814T (pt) * 2007-02-15 2019-11-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
CN103660089B (zh) 2007-10-12 2017-04-12 流体科技公司 用于生产颗粒和图案化膜的系统和方法
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CN102301463B (zh) 2008-12-05 2015-12-02 流体科技公司 产生有图案的材料的方法
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
RU2565445C2 (ru) * 2010-01-22 2015-10-20 Аллерган, Инк. Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
EP3342380A3 (en) * 2012-03-26 2018-11-14 Glaukos Corporation System and method for delivering multiple ocular implants
US20130256354A1 (en) 2012-03-27 2013-10-03 Michael Dane Clark Secure hanger
US9120270B2 (en) 2012-04-27 2015-09-01 University Of Southern California Digital mask-image-projection-based additive manufacturing that applies shearing force to detach each added layer
WO2014066658A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
MY177958A (en) * 2013-10-31 2020-09-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof

Also Published As

Publication number Publication date
WO2015085251A1 (en) 2015-06-11
US20220080049A1 (en) 2022-03-17
MX2016007345A (es) 2016-12-09
JP6546194B2 (ja) 2019-07-17
AU2014360184B2 (en) 2020-07-23
KR20160100992A (ko) 2016-08-24
JP2016540055A (ja) 2016-12-22
AU2014360184A1 (en) 2016-07-21
EP3861982A2 (en) 2021-08-11
EP3076948A1 (en) 2016-10-12
EP3076948B1 (en) 2020-11-18
US20160296627A1 (en) 2016-10-13
EP3076948A4 (en) 2017-08-02
EP3861982A3 (en) 2021-09-01
CN106132397A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
US20220080049A1 (en) Intracameral implant for treatment of an ocular condition
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
CA2846384C (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US20230285188A1 (en) Glaucoma treatment via intracameral ocular implants
US20100274224A1 (en) Lacrimal implant body including comforting agent
CN105073153B (zh) 含有前列腺胺的眼内植入物
US20120276186A1 (en) Sustained release latanoprost implant
CN107184544A (zh) 前房内持续释放治疗药植入物
JP2011525388A (ja) 緑内障の併用治療
KR20210135560A (ko) 안구 질환 또는 장애를 치료하는 약학 조성물
US20240216512A1 (en) Intracameral implant for treatment of an ocular condition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191203

FZDE Discontinued

Effective date: 20220819

FZDE Discontinued

Effective date: 20220819